paul
Researcher
Posts: 134
|
Post by paul on Aug 14, 2019 14:39:00 GMT -5
I don't know, but I doubt prescribers will make an effort to prescribe without assistance from salesforce; especially since many of the prescriptions encounter Prior Authorization and/or STEP programs where it becomes more important for a high-touch support from the salespeople. Brings up an interesting question -- do the salespeople assist with handling prior authorization issues? Also curious -- do sales reps maintain twitter, facebook, and instagram accounts? Seems like those would be venues they could reach out to customers with.
|
|
|
Post by wgreystone on Aug 14, 2019 15:46:29 GMT -5
Nate's "take on it", I would say he votes with the current regime intact, buy under $10, strong buy under $5, and a pounding the table screaming buy under $2 In "other words", Nate can't see us "heading for the rocks"....I like Nate's resume a bit better, CLGN, AAPL, etc. Nates certainly get too obsessed with this stock. Over 40% of his aggressive portfolio net asset is in this stock.
|
|
|
Post by prcgorman2 on Aug 14, 2019 17:27:37 GMT -5
How's your portfolio doing versus Nate's? Maybe you can start an investor fund and newsletter too.
|
|
|
Post by wyattdog on Aug 14, 2019 17:37:59 GMT -5
spencerosborne Aug 14th, 2:32 pm $MNKD traders perspective.... I am bullish here. No cash overhang right now. Decision from United on deck in next few weeks. Should be a PR on Brazil shipment within next month. Possible pop to $1.30 or more in that timeframes. Put a mental stop at $0.95
|
|
|
Post by ryster505 on Aug 14, 2019 17:45:11 GMT -5
Nate's "take on it", I would say he votes with the current regime intact, buy under $10, strong buy under $5, and a pounding the table screaming buy under $2 In "other words", Nate can't see us "heading for the rocks"....I like Nate's resume a bit better, CLGN, AAPL, etc. Nates certainly get too obsessed with this stock. Over 40% of his aggressive portfolio net asset is in this stock. Smart man.
|
|
|
Post by sportsrancho on Aug 14, 2019 18:44:06 GMT -5
SO
Aug 12th, 9:38 am $MNKD the monthly minimum afrezza net revenue covenant can (in concept) be viewed as minimum afrezza net revenue guidance. Over the weekend I broke down the monthly into weekly. This gives the ability to track against projections as well as the more refined estimates (estimates are based on actual weekly data). The next 4-5 months are critical. My current projections have the company falling behind the curve in November. Essentially the growth curve of the covenant demands a higher rate of growth in this early stage. Bottom line... The Brazil launch needs to be very good.
Aug 14th, 9:21 am @longuntilshort it is a fine line to walk. I designed this article to allow HFM to present themselves in the manner they want without my opinion or stance getting in the way. This article was reviewed by them prior to publication. They had the ability to edit out anything they wanted. I respect that they did not cherry pick during that process. In my opinion the 35'000 foot view needed to be outlined, and getting into the weeds is a refinement discussion for later. If an investor is satisfied at the 35000 foot view, fine. If they want more detail, they at least have a knowledge platform to ask from. I will have a similar piece with mnkd management that I am working on now. These two pieces will not lay out all the answers, but will at least give investors reference points to consider.
|
|
|
Post by mytakeonit on Aug 14, 2019 18:51:47 GMT -5
40% isn't aggressive ... I'm at 100% . Now, that's AGGRESSIVE !!!
But, that's mytakeonit
|
|
|
Post by mango on Aug 15, 2019 12:14:12 GMT -5
Disappointed in Bill for working directly with SO.
Won't be giving Spencer a click, sorry.
|
|
|
Post by sportsrancho on Aug 15, 2019 12:24:41 GMT -5
Disappointed in Bill for working directly with SO. Won't be giving Spencer a click, sorry. [ Well then you’re going to be real disappointed in Mike next week because he’s doing it to. At least that’s what Spencer has told people on Stocktwits which I posted.
|
|
|
Post by sportsrancho on Aug 15, 2019 12:41:53 GMT -5
Disappointed in Bill for working directly with SO. Won't be giving Spencer a click, sorry. it is a fine line to walk. I designed this article to allow HFM to present themselves in the manner they want without my opinion or stance getting in the way. This article was reviewed by them prior to publication. They had the ability to edit out anything they wanted. I respect that they did not cherry pick during that process. In my opinion the 35'000 foot view needed to be outlined, and getting into the weeds is a refinement discussion for later. If an investor is satisfied at the 35000 foot view, fine. If they want more detail, they at least have a knowledge platform to ask from. I will have a similar piece with mnkd management that I am working on now. These two pieces will not lay out all the answers, but will at least give investors reference points to consider.
|
|
|
Post by ktim on Aug 15, 2019 14:33:39 GMT -5
I don't know about shutting down advertising, but I would be curious to see the effect of laying off all the sales reps for a month or two. That data is apparently available, just not to us. MNKD pulled sales reps from some states awhile ago.
|
|
|
Post by scottmnkd on Aug 16, 2019 12:20:20 GMT -5
I agree with Bill Mc. that MNKD needs to spend much less on its salesforce. The sales strategy has been woefully ineffective at this point and the company bleeds cash it doesn't have. I think we need to face the fact that the US market has too many hurdles at this time to effectively sell Afrezza. With Brazil and Australia coming on line with a partner, it'll be interesting to see how well those markets develop. Also, once the pediatric trials are completed that may help too.
I don't think that anybody would disagree that Afrezza is the best mealtime insulin on the market. But, going through normal sales channels is fruitless. Mike C and company should painfully realize this now and find an alternate strategy.
Personally, just I'm glad that the pipeline is growing and now see Afrezza as being less the focus as other developments with RS and UTHR. This morning's scripts were the typical disaster and while disappointing - expected. So, I'll be delighted if Afrezza eventually becomes the SOC, but I've mentally moved onto other aspects that keep my investment in MNKD interesting.
|
|
|
Post by lennymnkd on Aug 16, 2019 12:37:47 GMT -5
Agree , the door to door sales approach seems antiquated in this day and age ...technology etc.. has that Jehovah witness.. door to door approach/ no disrespect/ not for just mnkd/ afrezza but pharma in general. All you hear is how busy the doctors are ! No time to see a rep .. the old I’ll be back I’ll get lunch first ; there has to be a better way .
|
|
paul
Researcher
Posts: 134
|
Post by paul on Aug 16, 2019 13:00:43 GMT -5
Agree , the door to door sales approach seems antiquated in this day and age ...technology etc.. has that Jehovah witness.. door to door approach/ no disrespect/ not for just mnkd/ afrezza but pharma in general. All you hear is how busy the doctors are ! No time to see a rep .. the old I’ll be back I’ll get lunch first ; there has to be a better way . Last week I was in my doctor's office and two drug reps walked in one after the other. Each one went to the registration desk and handed over some sort of little tablet like device. The receptionist disappeared for a minute, then came back and handed the tablets back to the reps who then left.
Obviously, the doctor just signed the pads to confirm that he had "seen" the reps. They didn't even hand over any literature or samples. It was a total waste of time for all concerned.
|
|
|
Post by sportsrancho on Aug 16, 2019 17:22:27 GMT -5
Comment section of article:
As the original deal lead and 6 year BOD member of a start-up I have no reticence in wholeheartedly supporting Bill McCullough and HFM fully. Though we had a smaller company in the financial sector our problems, after eight years of lagging sales and cancerous budgets, were very similar.
We had a founding CEO and Chairman who is very likable, and politic. Like Mann, he had great vision in perceiving a market need but did not have, and was not willing to admit his lack of management ability, the agility and flexibility that a small company requires. I might add that, though initially resisting, he was relatively amiable, and helpful, and maybe even relieved when he saw that his successor seemed to have a suitable skill set and experience. He just needed the push out the door. He wasn't going to admit his failure on his own. It is not the nature of entrepreneurs and managers in general to do so.
McCullough is correct, but he is too generous by a large measure to excuse these undoubtedly smart individuals for simple having ‘insider tunnel vision’. Time and again you see it, in tiny start-ups to giant public firms, managers knowing that they are headed for a cliff and they change nothing. It is human nature, in business and politics, to subconsciously measure the world around one by the standard of their own agenda. In the end they rationalize that they did all they could. Balderdash!
So you see in Mannkind, as I’ve seen in over 30 start-ups, BOD members, enamored by the prestige of their position and satisfied to be paid for doing nothing. They agree with Management to raise round after round of funding, ultimately only to pay their bloated salaries as if they were running a profitable enterprise.
No one holds MNKD shares because he imagines that it is a low risk investment. But as a 41 year derivatives trader and investor I know that 'No decision is worse that a bad decision'. The latter can be corrected - the former, by definition, never will be.
A wholesale housecleaning is called for. If the opportunity to throw my support to HFM arises I will take the time to deliver my proxies. I might even buy more shares to do so.
Ruven77
|
|